ABSTRACT
To elucidate structure-activity relationships for drugs that are able to poison or inhibit topoisomerase II, we investigated the thermodynamics and stereochemistry of the DNA binding of a number of anthracene derivatives bearing one or two 4,5-dihydro-1H-imidazol-2-yl-hydrazine side chains (characteristic of bisantrene) at different positions of the planar aromatic system. An aza-bioisostere, which can be considered a bisantrene-amsacrine hybrid, was also tested. The affinity for nucleic acids in different sequence contexts was evaluated by spectroscopic techniques, using various experimental conditions. DNA-melting and Dnase I footprinting experiments were also performed. The location and number of the otherwise identical side chains dramatically affected the affinity of the test compounds for the nucleic acid. In addition, the new compounds exhibited different DNA sequence preferences, depending on the locations of the dihydroimidazolyl-hydrazine groups, which indicates a major role for the side-chain position in generating specific contacts with the nucleic acid. Molecular modeling studies of the intercalative binding of the 1- or 9-substituted isomers to DNA fully supported the experimental data, because a substantially more favorable recognition of A-T steps, compared with G-C steps, was found for the 9-substituted derivative, whereas a much closer energy balance was found for the 1-substituted isomer. These results compare well with the alteration of base specificity found for the topoisomerase II-mediated DNA cleavage stimulated by the isomeric drugs. Therefore, DNA-binding specificity appears to represent an important determinant for the recognition of the topoisomerase-DNA cleavable complex by the drug, at least for poisons belonging to the amsacrine-bisantrene family.

DNA topoisomerase II is a ubiquitous enzyme that regulates DNA topological features; during its catalytic cycle, it cleaves a DNA duplex, allows the passage of another DNA segment through the cut, and finally reseals the strand breaks (Berger et al., 1996). Eukaryotic type II topoisomerases are the targets of highly effective antitumor drugs such as m-AMSA, bisantrene, anthracyclines, and etoposide. The pharmacological activity of these antitumor compounds is thus related to DNA cleavage stimulation in living tumor cells (Pommier, 1993).

Several lines of evidence indicate that topoisomerase II poisons bind to the enzyme/DNA interface at the site of DNA cleavage (Capranico et al., 1997). These drugs are commonly composed of a planar ring system, with DNA-intercalation or -intercalation-like properties, and one or two protruding side chains, which are believed to recognize the enzyme side of the cleavable complex (Osheroff et al., 1994). However, these drugs do not share a unique pharmacophore (Capranico et al., 1997) and can only define a “loose” one, as earlier suggested (Leteurtre et al., 1992). The lack of structural restrictions for the pharmacophore of topoisomerase II poisons can mainly be ascribed to receptor heterogeneity, which is determined by the variability of the local nucleic acid sequence at the enzyme/DNA interface. This is reflected in marked differences of cleavage patterns observed in sequencing gels and local base preferences among the different classes of chemical poisons (Capranico et al., 1990, 1993; Pommier et al., 1991).

The financial support of Associazione Italiana per la Ricerca sul Cancro is gratefully acknowledged.

ABBREVIATIONS: m-AMSA, 4’-(9-acridinyldimino)methanesulfon-m-anisidine; 9-IHA, anthracene-9-carboxaldehyde-(4,5-dihydro-1H-imidazol-2-yl)hydrazine hydrobromide; aza-9-IHA, 9-acridinecarboxaldehyde-(4,5-dihydro-1H-imidazol-2-yl)hydrazine hydrobromide; 1-IHA, anthracene-1-carboxaldehyde-(4,5-dihydro-1H-imidazol-2-yl)hydrazine hydrobromide; 1,4-IHA, anthracene-1,4-dicarboxaldehyde-(4,5-dihydro-1H-imidazol-2-yl)hydrazine hydrobromide; DS, DNA binding specificity; TS, topoisomerase II-mediated sequence specificity; T_m, melting temperature.
In previous attempts to define the structural determinants of this important family of anticancer agents, we demonstrated that, although many chemically unrelated poisons can stimulate DNA cleavage in the presence of topoisomerase II, only compounds sharing common steric and electronic features can trap the enzyme at the same nucleic acid sites (Capranico et al., 1994). This is the case for bisantrene and m-AMSA, which have identical A+1 base requirements for topoisomerase II-mediated DNA cleavage stimulation. In fact, a remarkable similarity in space occupancy and charge distribution was demonstrated for the two compounds, which might account for the equivalent base requirements (Capranico et al., 1994). Stimulated by these findings, we recently investigated a number of bisantrene congeners, including a 10-aza-bioisoster, bearing the same 4,5-dihydro-1H-imidazol-2-yl-hydrazone side chain at positions 1, 4, or 9 of anthracyene (Capranico et al., 1998). Moving the bisantrene side chain along the planar ring system (from C9 and C5 to C1 and C4) dramatically affected the base preference and intensity patterns of poison-stimulated DNA cleavage. In contrast, switching the planar aromatic systems of bisantrene and m-AMSA did not substantially alter the sequence specificity of drug action. Base preferences at the cleavage site are reported in Table 1. Indeed, a common pharmacophore was shared by bisantrene, m-AMSA, and the 9-substituted analogues, whereas the 1-substituted regioisomer showed radically changed pharmacophoric properties.

Because topoisomerase poisons, including m-AMSA, likely interact at the protein/DNA interface (Freudenreich and Kreuzer, 1994; Capranico et al., 1997), their DNA-binding activity can be affected by the structural and chemical changes induced by protein/nucleic acid contacts. In the case of anthracyclines, the base preferences exhibited by the drug for naked DNA and for the topoisomerase II-DNA complex are different, indicating that alterations of the drug interaction with the double helix occur in the ternary complex. Amscarcine, on the other hand, shows the same (5-TA) dinucleotide preference for binding to protein-free DNA and for stabilizing the enzyme-DNA complex (Chen et al., 1988; Pommier et al., 1991). Hence, a thorough understanding of the structural and functional aspects of the effects of the protein on poison-DNA interactions is still missing. In this connection, we were interested in investigating the DNA-binding affinity and specificity of the series of bisantrenem-m-AMSA congeners shown in Fig. 1 and comparing them with the sequence preferences found in the topoisomerase II-poisoning experiments (Capranico et al., 1998).

We show that not only the affinity for the nucleic acid is affected; the DS is also dramatically modified upon movement of the side-chain groups along the anthracyene ring system. Most interestingly, the changes in specificity exhibited by structural isomers in the binary drug-DNA system precisely correspond to the specificity changes observed for enzyme-mediated DNA cleavage. This information could facilitate further elucidation of the details of the mechanism of action of topoisomerase poisons and will be valuable in the rational design of novel poisons with a predefined site selectivity for DNA cleavage.

**Experimental Procedures**

**Materials.** m-AMSA and bisantrene were obtained from the Drug Synthesis and Chemistry Branch, National Cancer Institute (Bethesda, MD), and from Lederle, respectively. The imidazolyl-hydrazone compounds were synthesized as described elsewhere (Zagotto et al., 1998). All compounds used were stored at −20° in dimethylsulfoxide or deionized water and were diluted in deionized water before use.

The three natural DNAs, from calf thymus (highly polymerized sodium salt), Clostridium perfringens, and Micrococcus lysodeikticus, as well as pBR322 plasmid and double-stranded polynucleotides, were purchased from Pharmacia (Milan, Italy) or Sigma Chemical Co. (St. Louis, MO). Their concentrations were determined by applying the molar extinction coefficients reported in the literature (Grant et al., 1968; Wells et al., 1970). DNAs and polynucleotides were used without purification except for calf thymus DNA, which was deproteinized twice with sodium dodecyl sulfate. After purification, the protein content was <0.2% and did not interfere with the present results. All DNAs were dialyzed at 4° against Tris or BPE buffer (6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM EDTA, pH 7.1) before use.

Single-stranded DNA (ε = 8350 M−1 cm−1) was provided by Crinos S.p.A. (Villaguardia, Italy). DNA topoisomerase II was purified from the nuclei of murine P388 cells and stored as described (De Isabella et al., 1990). Simian virus 40, restriction enzymes, the DNA-modify-

**Table 1**

<table>
<thead>
<tr>
<th>Position from the cleaved bond</th>
<th>Base</th>
<th>−log P^a</th>
<th>m-AMSA</th>
<th>9-IHA</th>
<th>1-IHA</th>
</tr>
</thead>
<tbody>
<tr>
<td>−1</td>
<td>A</td>
<td>−0.4</td>
<td>−0.9</td>
<td>−0.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>G</td>
<td>+0.6</td>
<td>−0.4</td>
<td>−0.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>+0.4</td>
<td>+2.0</td>
<td>+1.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T</td>
<td>−0.5</td>
<td>−0.5</td>
<td>−0.5</td>
<td></td>
</tr>
<tr>
<td>+1</td>
<td>A</td>
<td>+2.7</td>
<td>+2.5</td>
<td>+1.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>G</td>
<td>−0.6</td>
<td>−0.6</td>
<td>+0.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>−0.6</td>
<td>+0.3</td>
<td>−0.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T</td>
<td>−0.9</td>
<td>−1.8</td>
<td>−1.0</td>
<td></td>
</tr>
</tbody>
</table>

^a Enzyme-mediated cleavage occurs between positions −1 and +1.

^b Negative logarithm of the probability of observing that deviation or more as either an excess (positive numbers) or deficiency (negative numbers), relative to the expected base frequency in simian virus 40 DNA. Weakly and strongly stimulated sites were analyzed. The numbers of sites analyzed were 126, 66, and 37 for m-AMSA, 9-IHA, and 1-IHA, respectively.

![Fig. 1. Chemical structures of the test drugs.](image)
ing enzymes, agarose, and acrylamide were from GIBCO-BRL (Gaithersburg, MD) or from New England Biolabs (Beverly, MA).

Nucleoside triphosphates labeled with $^{32}$P ([α-$^{32}$P]ATP and [γ-$^{32}$P]ATP; 3000 Ci/mmol) were obtained from Amersham (Milan, Italy). The restriction endonucleases AvaI, EcoRI, HindIII, and PvuII, alkaline phosphatase, T4 polynucleotide kinase, and avian myeloblastosis virus reverse transcriptase were purchased from Boehringer (Mannheim, Germany) and were used according to the protocol recommended by the supplier, in the activity buffer provided. All other chemicals were analytical grade reagents, and all solutions were prepared using doubly deionized, filtered (Millipore filter) water.

**Stability of the test drugs in aqueous media.** All compounds were stable in aqueous solution at the working concentrations and did not undergo self-aggregation phenomena up to at least 100 μM. A notable exception was 1,4-IHA, whose molar extinction coefficient decreased with increasing concentration. This phenomenon has been described for molecules containing hydrophobic planar systems that could stack on each other, including bisantrene and mitoxantrone. The dependence of the extinction coefficient on the drug concentration was investigated at different ionic strengths. The experimental data obtained by spectroscopic titrations were consistent with a model of indefinite aggregation (Schwartz et al., 1970), which takes into account aggregation processes beyond a simple monomer-dimer equilibrium. As could be anticipated, considering the presence of protonated side chains, with increasing ionic strength the drug charge becomes shielded, which reduces the repulsive effect and stabilizes the aggregates. An association constant value of approximately $10^4 \text{ M}^{-1}$ was found.

**DNA binding studies.** Measurements were carried out at 25° in ETN buffer (1 mM EDTA, 10 mM Tris, pH 7.0, with NaCl to obtain the desired ionic strength). Binding was monitored spectrophotometrically or fluorometrically, in the ligand absorption or emission region, respectively, after addition of scalar amounts of DNA to a freshly prepared drug solution. To avoid large systematic inaccuracies resulting from experimental errors in extinction coefficients or fluorescence quantum yield, the range of bound drug fractions was 0.15–0.85. Data were evaluated according to the equation of McGhee and Von Hippel (1974) for noncooperative ligand-lattice interactions,

$$r/n = K_i(1 - m^n)/(1 - (n - 1)r)^{n-1}$$

where $r$ is the molar ratio of bound ligand to DNA, $m$ is the free ligand concentration, $K_i$ is the intrinsic binding constant, and $n$ is the exclusion parameter. Spectroscopic measurements were made with a Perkin-Elmer Lambda 5 apparatus and a MPF66 fluorometer, both equipped with a Haake F3-C thermostat.

**Tm studies.** Melting curves were measured using a Uvikon 943 spectrophotometer coupled to a Neslab RTE111 cryostat. For each series of measurements, 12 samples were placed in a thermostatically controlled cell-holder (path length, 10 mm), and the quartz cuvettes were heated by circulating water. The measurements were made in BPE buffer (pH 7.1). The temperature inside the cuvette was monitored by using a thermocouple in contact with the solution. The absorbance at 260 nm was measured over the range of 20–100°, with a heating rate of 1°/min. The $T_m$ was taken as the midpoint of the hyperchromic transition.

**DNA-unwinding assays.** Plasmid DNA (pBR322) was incubated for 30 min with increasing concentrations (0–100 μM) of 9-IHA, aza-9-IHA, and 1-IHA. Aliquots containing 400 ng of DNA (10 μl) were then loaded onto 1% agarose gels, after addition of 2 μl of loading buffer (0.01% bromphenol blue, 0.01% xylene cyanol, 40% sucrose). Gels were run in TBE buffer (89 mM Tris-borate, pH 8.3, 1 mM EDTA) at 10 V/cm. The gels were then stained with ethidium bromide (0.5 mg/liter) and scanned using a BioRad Gel Doc 1000 system.

**DNA purification and labeling.** Plasmid pBS (Stratagene) was isolated from *Escherichia coli* by a standard sodium dodecyl sulfate-sodium hydroxide lysis procedure and was purified by banding in CsCl-ethidium bromide gradients. Ethidium was removed by several isopropanol extractions followed by exhaustive dialysis against Tris-EDTA buffer. The purified plasmid was then precipitated and resuspended in appropriate buffer before digestion with the restriction

**Fig. 2.** Examples of spectrophotometric (A) and fluorometric (B) titration experiments for the binding of test drugs to double-stranded DNA from calf thymus, in ETN buffer (0.1 M, pH 7.0). Curve 1, free drug; curve 2, totally bound drug. A, 1-IHA (15.3 μM); B, aza-9-IHA (1.6 μM).

**TABLE 2**

Thermodynamic binding properties of test compound binding to calf thymus DNA in ETN buffer at different ionic strengths (pH 7.0, 25°)

The values of the exclusion parameter $n$ were close to 2 base pairs in all cases. They were slightly less than 2 for 1-IHA at low salt concentrations (0.022–0.1 M); this fact probably reflects modest external stacking of the drug when bound to DNA.

<table>
<thead>
<tr>
<th>Compound</th>
<th>$K_i$ ($10^{-4}n^m$)</th>
<th>0.022 M</th>
<th>0.10 M</th>
<th>0.25 M</th>
<th>0.50 M</th>
<th>$m$</th>
<th>$-\Delta G^\ddagger$</th>
</tr>
</thead>
<tbody>
<tr>
<td>9-IHA</td>
<td>59.5 ± 2.8</td>
<td>17.6 ± 1.9</td>
<td>4.64 ± 0.4</td>
<td>ND$^a$</td>
<td>1</td>
<td>5.6</td>
<td></td>
</tr>
<tr>
<td>Aza-9-IHA</td>
<td>61.7 ± 2.8</td>
<td>18.0 ± 1.8</td>
<td>6.59 ± 0.5</td>
<td>ND</td>
<td>1</td>
<td>5.8</td>
<td></td>
</tr>
<tr>
<td>1-IHA</td>
<td>17.6 ± 1.6</td>
<td>5.61 ± 0.5</td>
<td>2.35 ± 0.2</td>
<td>0.78 ± 0.1</td>
<td>1</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>Bisantrene</td>
<td>ND</td>
<td>660 ± 31</td>
<td>113 ± 4.8</td>
<td>20.1 ± 2.0</td>
<td>2</td>
<td>6.6</td>
<td></td>
</tr>
</tbody>
</table>

$^a$ Intrinsic binding constant.

$^b$ The number of ionic contacts per complex unit, calculated from the slope $\partial \log K_i/\partial \log$ (ionic strength) (Fig. 5).

$^c$ Interaction free energy corrected for the electrostatic contribution.

$^d$ Ionic strength.

$^e$ ND, not determined.
enzymes. The 265-base pair DNA fragment was prepared by 5'-32P-end-labeling of the EcoRI/alkaline phosphatase-treated plasmid using [γ-32P]ATP (6000 Ci/mmol) and T4 polynucleotide kinase, followed by treatment with PvuII. The digestion products were separated on a 6% polyacrylamide gel under native conditions in TBE buffer. After autoradiography, the band of DNA was excised, crushed, and soaked in elution buffer (500 mM ammonium acetate, 10 mM magnesium acetate) overnight at 37°C. This suspension was filtered through a Millipore 0.22-μm filter, and the DNA was precipitated with ethanol. After washing with 70% ethanol and vacuum drying of the precipitate, the labeled DNA was resuspended in 10 mM Tris (adjusted to pH 7.0) containing 10 mM NaCl.

**DNase I footprinting experiments.** Experiments were performed essentially as previously described (Bailly and Waring, 1995). Briefly, reactions were conducted in a total volume of 10 μl. Samples (3 μl) of the labeled DNA fragment were incubated with 5 μl of the buffer solution containing the ligand at the appropriate concentration. After 30 min of incubation at 37°C to ensure equilibration of the binding reaction, the digestion was initiated by the addition of 2 μl of a DNase I solution, the concentration of which was adjusted to yield a final enzyme concentration of approximately 0.01 unit/ml in the reaction mixture. After 3 min, the reaction was stopped by freeze-drying. Samples were lyophilized and resuspended in 5 μl of an 80% formamide solution containing tracking dyes. The DNA samples were then heated at 90°C for 4 min and chilled on ice for 4 min before electrophoresis.

**Electrophoresis and quantitation by storage phosphor imaging.** DNA cleavage products were resolved by polyacrylamide gel electrophoresis under denaturing conditions (0.3-mm thick gels, 8% acrylamide containing 8 M urea). After electrophoresis (approximately 2.5 hr at 60 W and 1600 V in TBE buffer; BRL sequencer model S2), gels were soaked in 10% acetic acid for 10 min, transferred to Whatman 3MM paper, and dried under vacuum at 80°C. A Molecular Dynamics 425E PhosphorImager was used to collect data from the storage screens exposed to dried gels overnight at room temperature. Base-line-corrected scans were analyzed by integrating all densities between two selected boundaries using ImageQuant version 3.3 software. Each resolved band was assigned to a particular bond within the DNA fragment by comparison of its position with those of sequencing standards generated by treatment of DNA with dimethylsulfate (guanine) and/or formic acid (guanine plus adenine), followed by pipidine-induced cleavage at the modified bases in the DNA.

**Molecular modeling.** This study involved the use of the consensus dinucleotide intercalation geometries (dApT) and (dGpC), which were initially derived from the crystal structures of adriamycin (Frederick et al., 1990) and proflavine (Neidle et al., 1988) intercalation complexes, respectively. The dApT) and (dGpC) intercalation sites were located at the center of a decanucleotide duplex having the sequence d(5'-ATATA-3')2 and d(5'-GCCGG-3')2. Decamers in the B-form were built using the nucleic acid builder function of the HyperChem software program (release 4.5; Hypercube Inc., Gainesville, FL). Both decanucleotides were minimized using the Amber all-atom force field (Weiner et al., 1986) of the Macromod 5.0 molecular modeling package (Mohamadi et al., 1990), until the root mean square of the conjugate gradient was <0.05 kcal/mol/Å. The dielectric constant was assumed to be distance independent, with a magnitude of 4.

1-HA and 9-HA geometries were fully optimized, without geometry constraints, using RHF/3-21G(*) (Hohre et al., 1986) ab initio calculations Vibrational frequency analysis was used to characterized the minima stationary points (zero imaginary frequencies). The Spartan software package (release 4.2; Wavefunction Inc., Irvine, CA) was used for all quantum mechanical calculations.

1-HA and 9-HA structures were rigidly docked into the intercalation site without relaxing the atomic coordinates of either ligand or nucleotide. The side-chain groups were alternatively located in the minor groove or in the major groove. The resulting DNA-ligand intercalated complexes were subjected to Amber all-atom energy minimization until the root mean square of the conjugate gradient was <0.01 kcal/mol/Å. Charges for the ligands were imported from the Spartan output files.

The interaction energy values were calculated as follows: \[ \Delta E_{\text{intercalation}} = E_{\text{complex}} - (E_L + E_{\text{ligand}}). \] These energies do not correspond to the real energetic value in a rigorous thermodynamic way. They can only be compared with each other in terms of more or less favorable states. All molecular modeling calculations were performed with an IBM RISC System 6000 model 250 Unix workstation.

**Results**

**Thermodynamics of DNA Binding**

**Spectroscopic studies.** Upon addition of DNA (polynucleotide) solutions, all test compounds exhibited dramatic changes in their spectroscopic properties. In particular, the fluorescence of 9-IHA andaza-9-IHA was progressively quenched (Fig. 2B), and the absorption spectrum of 1-IHA underwent a bathochromic and hypochromic shift, generating an isosbestic point (Fig. 2A). The case of 1,4-IHA deserves additional comment. The drug tends to aggregate to a remarkable extent (see Experimental Procedures) and was very effective in inducing DNA condensation and precipitation even at the lowest binding ratios examined. Therefore, a quantitative evaluation of the DNA binding constants for this compound was not possible, but it can be safely stated that this drug exhibits a very high affinity for the nucleic acid under the experimental conditions used.

Analysis of the binding data yielded the thermodynamic

![Fig. 3. Dependence of the binding constant Ki for the test congeners on ionic strength (IS).](image_url)
parameters reported in Table 2. The novel compounds exhibited binding affinities on the order of $10^5 \text{ M}^{-1}$, with 9-IHA and aza-9-IHA closely resembling each other and 1-IHA showing a 3-fold lower interaction constant, compared with its isomeric congeners. On the other hand, in agreement with previous reports (Denny and Wakelin, 1987; Wunz et al., 1990), bisantrene showed an outstanding ability to form a complex with DNA. Its binding constant at the various experimental conditions was always almost 2 orders of magnitude greater than the constants of monosubstituted congeners.

Considering the charged nature of the side chains of the drugs, the use of different ionic strengths allowed us to evaluate the electrostatic contribution of ionic interactions to the binding process. All drugs showed a linear relationship of log $K_i$ versus log ionic strength (Fig. 3). Using the polyelectrolyte theory adapted to nucleic acids (Record et al., 1978), it was possible to confirm that one charged interaction occurs in the DNA binding of compounds bearing one dihydroimidazolyl side chain ($m' = 1$), whereas two ion pairs effectively neutralize the negative charge density of the nucleic acid in the case of bisantrene ($m' = 2$). In addition, the interaction free energy corrected for the electrostatic interactions could be evaluated according to the following equation (Record et al., 1978):

$$\ln K_i = \ln K^\circ + m' \xi^{-1} \ln(\gamma \pm \delta) - m' \phi \ln[M^+]$$

where $K_i$ is the binding constant calculated at a given salt concentration, $K^\circ$ is the constant corrected for ion release, $\xi$, and $\delta$ are known physical parameters (0.88, 4.2, and 0.56, respectively, for native DNA), and $\gamma$ is the activity coefficient of $M^+$, the added salt, at the given ionic strength. Bisantrene exhibits the most effective binding (even neglecting electrostatic contacts), followed by the 9-substituted compounds and finally by 1-IHA.

**Mode of interaction.** Compounds 9-IHA, aza-9-IHA, and 1-IHA were examined for their abilities to affect the electrophoretic mobility of supercoiled plasmid DNA. As expected from the close structural similarities with the parent drugs, which are well known intercalators, all of them caused a progressive decrease of plasmid mobility in the gel, followed by a leveling off and finally an increase with increasing drug concentration (data not shown). This behavior is clearly indicative of an intercalating mechanism of binding for the test drugs.

**Binding to single-stranded DNA.** To evaluate the effect of DNA structure on the binding efficiency of the test drugs, we also determined the affinity constants with single-stranded nucleic acid. The quantitative data are reported in Table 3. Interestingly, bisantrene congeners retained a remarkable capacity for binding to the single-stranded structure. In comparison with the $K_i$ values found for double-stranded DNA, 9-IHA showed a 2-fold increase, 1-IHA maintained the same values, and aza-9-IHA exhibited a modest reduction. On the other hand, bisantrene, although undergoing a 6-fold reduction in $K_i$, still exhibited an affinity constant of the order of $10^6 \text{ M}^{-1}$.

**Melting experiments.** Effective intercalating drugs are well known for their ability to shift the $T_m$ of double-stranded DNA to higher values (Foye et al., 1986). Although increases in $T_m$ cannot be immediately correlated with binding stability, high $\Delta T_m$ values are indicative of tight interactions. The results of melting experiments performed with the test drugs using a number of natural and synthetic DNAs are reported in Table 4. No useful data could be obtained with poly(dG-dC) because of the very high $T_m (=97^\circ)$ exhibited by the polynucleotide. Values of $\Delta T_m$ always increased with increasing drug concentration and were as high as 44° in the case of 1,4-IHA, whereas they never exceeded 21° for the monosubstituted congeners. Considering that $\Delta T_m$ values for bisantrene did not exceed 42°, this confirms the outstanding DNA-binding efficiency of the 1,4-disubstituted analogue, in agreement with the results presented above.

In addition, and again in agreement with the thermodynamic data, 9-IHA and its aza-analogue showed very similar melting effects with all DNAs tested. Moreover, 1-IHA was always less effective than 9-IHA (and aza-9-IHA) in increasing the $T_m$, which confirms its lower binding affinity.

Regarding the possible effects of DNA composition, it should be emphasized that the various DNAs used in these experiments exhibit considerably different $T_m$ values (ranging from 35° to 75°). It is important to remember that the DNA binding constant is temperature dependent (in general, it decreases with increasing temperature), so that at given drug and DNA concentrations the amount of DNA-bound drug is different at different temperatures. In particular, for

### TABLE 4

Effects of the test compounds on the melting of polydeoxyribonucleotides and natural DNAs in BPE buffer (pH 7.1)

<table>
<thead>
<tr>
<th>Compound</th>
<th>9-IHA $\Delta T_m$ (°)</th>
<th>Aza-9-IHA $\Delta T_m$ (°)</th>
<th>1-IHA $\Delta T_m$ (°)</th>
<th>1,4-IHA $\Delta T_m$ (°)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 µM $^a$</td>
<td>5 µM $^b$</td>
<td>10 µM $^b$</td>
<td>2 µM $^a$</td>
</tr>
<tr>
<td>Poly(dA-dT) · (dA-dT)</td>
<td>11.8</td>
<td>16.5</td>
<td>21.3</td>
<td>10.8</td>
</tr>
<tr>
<td>Poly(dT-dC) · (dA-dC)</td>
<td>7.8</td>
<td>12.8</td>
<td>13.7</td>
<td>7.8</td>
</tr>
<tr>
<td>Poly(dT-dC) · (dC-dT)</td>
<td>2.0</td>
<td>3.0</td>
<td>4.9</td>
<td>1.0</td>
</tr>
<tr>
<td>Poly(dA-dG) · (dG-dC)</td>
<td>4.6</td>
<td>7.5</td>
<td>10.0</td>
<td>2.8</td>
</tr>
<tr>
<td>Clorostaphyum perfringens</td>
<td>5.4</td>
<td>9.1</td>
<td>9.7</td>
<td>4.0</td>
</tr>
<tr>
<td>Calf thymus DNA</td>
<td>3.8</td>
<td>4.7</td>
<td>5.9</td>
<td>1.9</td>
</tr>
<tr>
<td>Micrococcus lysodeikticus DNA</td>
<td>4.2</td>
<td>5.4</td>
<td>7.7</td>
<td>0.8</td>
</tr>
</tbody>
</table>

$^a$ Drug concentration.  
$^b$ Drug/DNA ratio.

The $T_m$ values for native DNA and polynucleotides were 41.1° for poly(dA-dT) · poly(dA-dT), 34.7° for poly(dG-dC) · poly(dG-dC), 66.7° for poly(dA-dC) · poly(dG-dT), 58.5° for poly(dA-dG) · poly(dC-dT), 58.5° for Clorostaphyum DNA (72% AT), 68.6° for calf thymus DNA (42% AT), and 74.7° for Micrococcus DNA (26% AT).
exothermic binding reactions. DNAs with low \( T_m \) values (e.g., poly(dA-dT)) show greater \( T_m \) effects than do DNAs with high \( T_m \) values (e.g., \( M. \ lysodeikticus \) DNA). Indeed, to properly assess base preferences, one should be able to monitor melting effects at constant levels of drug binding (rather than at constant concentrations of total (bound plus free) drug).

### DNA Sequence Selectivity

**Spectroscopic measurements.** Spectrophotometric and fluorometric methods were used to evaluate the affinities of the test drugs for DNAs with different base compositions. The results are reported in Table 5. 9-IHA and aza-9-IHA demonstrated a clear preference for A-T steps. In contrast, 1-IHA was able to bind to AT- or GC-rich DNAs almost equally well, losing the selectivity shown by the 9-substituted congeners. As expected from previous reports on intercalating ligands, binding of the test compounds to poly(purine)-poly(pyrimidine) sequences was substantially disfavored (data not shown).

**DNase I footprinting experiments.** Footprinting studies were performed to gain further insight into the sequence preferences exhibited by the tested anthracene derivatives. A representative example is shown in Fig. 4. The gel and the corresponding differential cleavage plots reveal that the nuclease activity was only slightly affected in the presence of 1-IHA and 1,4-IHA (20 \( \mu \)M each). Bisantrene exhibited a more pronounced effect (it was used at 5 \( \mu \)M), whereas both 9-IHA and aza-9-IHA showed absolutely no effects even at

![Fig. 4. DNase I footprinting with the 5'-end-labeled 265-mer \( PvuII-EcoRI \) restriction fragment cut from the plasmid pBS, in the presence of 5 \( \mu \)M bisantrene (Bst) or its derivatives (20 \( \mu \)M each). Control tracks (Cont) contained no drug. Guanine-specific sequence markers (G) obtained by treatment of the DNA with dimethylsulfate, followed by piperidine cleavage, were also run. Numbers at the top of the gels refer to the numbering scheme of the fragment. The differential cleavage plots compare the susceptibility of the fragment to DNase I cutting in the presence of bisantrene, 1-IHA, and 1,4-IHA. Negative values correspond to a ligand-protected site and positive values represent enhanced cleavage. The vertical scale is in units of \( \ln (i_f) - \ln (i_c) \), where \( i_f \) is the fractional cleavage at any bond in the presence of the drug and \( i_c \) is the fractional cleavage of the same bond in the control. Only the region of the restriction fragment analyzed by densitometry is shown. *, Sites of drug-induced enhanced reactivity toward DNase I.

### Table 5

<table>
<thead>
<tr>
<th>Compound</th>
<th>( K_i (\times 10^{-4}) )</th>
<th>9-IHA</th>
<th>Aza-9-IHA</th>
<th>1-IHA</th>
<th>1,4-IHA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calf thymus DNA</td>
<td>17.6 ± 1.9</td>
<td>31.0 ± 2.1</td>
<td>5.6 ± 0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poly(dA-dT)</td>
<td>18.0 ± 1.8</td>
<td>35.4 ± 2.2</td>
<td>16.8 ± 1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poly(dG-dC)</td>
<td>5.61 ± 0.5</td>
<td>12.5 ± 1.1</td>
<td>10.1 ± 1.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Intrinsic binding constant.

### Table 6

<table>
<thead>
<tr>
<th>L Oligomer</th>
<th>( E_{\text{L}} ) (kcal/mol)</th>
<th>( E_{\text{oligomer}} ) (kcal/mol)</th>
<th>( E_{\text{complex}} ) (kcal/mol)</th>
<th>( \Delta E_{\text{intercalation}} ) (kcal/mol)</th>
<th>( \Delta G^0 ) (kcal/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9-IHA</td>
<td>d(A-T/T-A)(_3)</td>
<td>-21.7</td>
<td>-1790.9</td>
<td>-1860.7</td>
<td>-48.1</td>
</tr>
<tr>
<td>1-IHA</td>
<td>d(A-T/T-A)(_3)</td>
<td>-5.9</td>
<td>-1790.9</td>
<td>-1825.9</td>
<td>-29.1</td>
</tr>
<tr>
<td>9-IHA</td>
<td>d(G-C/C-G)(_3)</td>
<td>-21.7</td>
<td>-2001.8</td>
<td>-2049.3</td>
<td>-25.8</td>
</tr>
<tr>
<td>1-IHA</td>
<td>d(G-C/C-G)(_3)</td>
<td>-5.9</td>
<td>-2001.8</td>
<td>-2039.6</td>
<td>-31.9</td>
</tr>
</tbody>
</table>

* \( \Delta E_{\text{intercalation}} = E_{\text{complex}} - (E_{\text{L}} + E_{\text{oligomer}}) \).

*Experimental values measured at 25°C, using the binding constants of Table 5.
concentrations as high as 100 μM (gel not shown). Quantitative analysis of the footprinting gels (the one shown in Fig. 4 and others with various DNA fragments) provided two interesting pieces of information. First, in the presence of the 1-substituted derivatives, but not with the 9-substituted congeners, the DNase I cleavage was enhanced at sequences containing contiguous A-T pairs. Both bisantrene and 1,4-IHA frequently promoted DNase I cleavage at oligopurine-oligopyrimidine tracts; conversely, they slightly reduced the cleavage activity at alternating purine-pyrimidine sequences. The preference for mixed purine-pyrimidine sequences is also apparent from the $T_m$ measurements. Indeed, much higher $\Delta T_m$ values were obtained with poly (dA-dC)poly(dG-dT) than with poly(dA-dG)poly(dC-dT) in the presence of 1,4-IHA (Table 4). Second, the sequences where cleavage by the nuclease was slightly reduced were neither GC- nor AT-rich. In most cases, they contained at least one $\overset{5}{\text{9}}$-GT-AC or $\overset{5}{\text{9}}$-TG-CA dinucleotide step. The footprinting data reinforce the conclusion, drawn from the spectroscopic measurements, that 1-IHA can bind to both AT- and GC-containing sequences. The lack of effective interference of the 9-substituted drugs with the cleavage of DNA by the enzyme was anticipated. It might be attributable to the relatively low affinity of the drugs and/or to the fast on and off kinetics. It is well known that amsacrine and related 9-aminoacridine analogues do not interfere with the DNase I cleavage reaction (Wakelin et al., 1990; Bailly et al., 1992; Crenshaw et al., 1995). Although DNase footprinting and topoisomerase stimulation experiments were performed with different DNA fragments, a comparison between them is significant because it is based on a statistical analysis.

Molecular Modeling Studies

Docking experiments were performed to calculate the energy changes and optimal geometries corresponding to the intercalative binding of 9-IHA and 1-IHA to A-T and G-C steps in a double-helical structure. In agreement with the binding experiments reported above, only alternating purine-pyrimidine steps were considered. In all cases, intercalation from the minor groove was preferred by 6–8 kcal/mol. The energy balance for the most favorable binding of 9-IHA and 1-IHA to A-T and G-C base pairs is presented in Table 6. Interestingly, an effective sequence discrimination appears to operate for 9-IHA; an energy difference of 22 kcal/mol was observed between intercalation into the more favored A-T step and that into the less preferred G-C step. In contrast, 1-IHA showed substantially reduced selectivity, with G-C steps being slightly favored (≈3 kcal/mol) over A-T steps. It should be emphasized that the calculated interaction energy values were approximated; they do not take into account entropy changes and solvation effects, which might provide relevant contributions to the binding process. It is, however, encouraging that the rank of calculated intercalation energies corresponds satisfactorily to the rank of experimentally determined free energies of binding (Fig. 5).

The structures corresponding to the most stable intercalation geometries of 9-IHA and 1-IHA are presented in Figs. 6

![Fig. 5. Relationship between the calculated energy of intercalation ($\Delta E$) and the experimental free energy of binding ($\Delta G$) corresponding to the interaction of 9-IHA (circles) and 1-IHA (squares) with A-T (closed symbols) and G-C (open symbols) polynucleotides.](image)

![Fig. 6. Best intercalation geometries for intercalation of 9-IHA and 1-IHA into A-T base pairs, as obtained from the docking experiments. Left, view from the minor groove; right, view along the DNA axis. Hydrogen atoms are not shown. Atoms of the drug structure are in black.](image)
and 7. In general, the side-chain groups protrude from the central part of the minor groove, producing effective electrostatic contacts with the negative charge density of the DNA. To optimize side-chain locations, the planar portions of the two drugs are considerably displaced in the intercalation pocket, with respect to each other. More efficient stacking interactions with A-T base pairs appear to be primarily responsible for the base preference exhibited by 9-IHA, compared with its 1-substituted isomer.

Discussion

The results obtained with the bisantrene congeners and presented here show unequivocally that the relative locations of the side chain and the planar ring system dramatically affect the affinity and specificity of these drugs for DNA. Loss of one of the two side chains of bisantrene clearly reduces binding to a major extent, which demonstrates the effective participation of both charged side-chain groups in the binding process. This is confirmed by the calculated value of 2 for the \( m' \) parameter (Table 2). The contribution of the dihydroimidazolyl lateral groups is not only electrostatic but must include noncharged contributions, as demonstrated by the \( \Delta G^\circ \) values extrapolated from the data measured at different ionic strengths. In fact, the \( \Delta G^\circ \) value for bisantrene is approximately 1 kcal/mol more negative than the \( \Delta G^\circ \) values for the 9-substituted analogues. The effects of bioisosteric substitution (C10 to N) essentially do not affect either \( K_r \) or \( \Delta G^\circ \). This indicates very similar arrangements of the planar moieties of 9-IHA and aza-9-IHA when the drugs are bound to DNA. On the other hand, a shift of the side chain from position 9 to position 1 reduces the interaction free energy (in absolute values) by an additional 1 kcal/mol (\( \Delta G^\circ = 5 \) kcal/mol). Hence, less favorable contacts occur between the drug and DNA when the dihydroimidazolyl group is located on the lateral rings of anthracene. The melting experiment results are in agreement with these findings. Unfortunately, because of the self-aggregation and DNA-precipitating ability of 1,4-IHA, it was not possible to make a sound comparison between this compound and the isomer bisantrene.

Not only the binding thermodynamics are affected by a shift of the side chain to a different position; the DS is also dramatically changed with movement of the lateral group from position 9 to position 1. As shown in Table 5, the strong preference of the 9-substituted compounds for A-T base pairs vanishes with the 1-substituted drug. This is confirmed by the docking experiment results, which indicate a more stable intercalation into A-T pairs for 9-IHA and an essential loss of discrimination for A-T versus G-C steps by 1-IHA. Further elucidation of sequence specificity, which was attempted with footprinting studies, was only marginally successful because of the poor footprinting ability of the monosubstituted derivatives. Nevertheless, these experiments confirm a wider sequence acceptance exhibited by 1-IHA.

With elucidation of the effects of the chain shift, in terms of DS, it is interesting to observe that DS and TS coincide for the test drugs. Indeed, whereas the 9-substituted compounds confirm the A+1 preference of m-AMSA and bisantrene, the 1-substituted congener does not show any specificity in stimulating DNA cleavage (Capranico et al., 1998) (Table 1). Recently, we have been interested in identification of the structural drug determinants for TS (Capranico et al., 1994; Palumbo et al., 1994). A key step in the enzyme-mediated mechanism of action is the formation of a ternary topoisomerase II-DNA-drug complex that establishes proper contacts between the drug pharmacophores and the enzyme and nucleic acid counterparts (Capranico et al., 1997). Although these contacts occur in a particular structure in which the original conformations of the macromolecular species are mutually distorted, some of the recognition features involved in binary drug-enzyme and drug-nucleic acid interactions should still be operative in the ternary system. In particular, for intercalating agents, the characteristics that allow preferential stacking onto given base pairs should also influence

![Fig. 7](https://example.com/fig7.png)
the locations at which drug-mediated cleavage stimulation occurs.

In the case presented here, it appears that, notwithstanding the changes occurring in the cleavable complex, recognition of DNA by the drug is preserved as it was in the absence of the enzyme. This fact is confirmed by the parallel changes in DS and TS that occur when the drug structure is isomerized.

The finding that TS corresponds to DS for the test drugs is even more surprising when we consider that the +1 specificity involves the base directly linked to the catalytic tyrosine (Capranico et al., 1997). Because of the special amino acid–nucleotide phosphodiester bond formed and the distortion caused by the new protein-linked arrangement, the base at +1 should be more profoundly affected (both electronically and structurally) than the base at position −1, with the latter remaining essentially paired in a double-helical conformation, as indicated by base-mismatch experiments (Bigioni et al., 1996). Indeed, considering that the central portion of the cleavage region (positions +1 to +4) must be melted to allow DNA strand-passing and that it is the religation step that is mainly inhibited by drugs such as m-AMSA (Robinson and Osheroff, 1991), it is possible that compounds having +1 specificity stabilize a catalytic intermediate in which the target base is unpaired. This is in line with the aforementioned base-mismatch experiments (Bigioni et al., 1996). In fact, whereas mismatches introduced at position −1, relative to the enzyme cleavage site, were shown to abolish DNA cleavage, those at positions +1 and +2 increased the level of DNA breakage instead. In the single-stranded region of DNA in the cleavable complex, the creation of efficient π interactions between the planar systems of the preferred base and of the drug should be crucial to avoid dissociation from the cleavable complex and loss of cleavage stimulation. Hence, efficient recognition of the DNA by the drug system through stacking interactions at position +1 in the cleavable complex should correlate with the base preferences in the enzyme-free system. This was, indeed, our observation. Moreover, the remarkable affinities shown by bisantrene and its congeners for stacking interactions with single-stranded DNA (Table 3) are consistent with the proposed recognition mechanism. In agreement with this concept, only purine bases, which exhibit an extended stacking surface, were previously found to be preferred for cleavage stimulation at position +1, whereas any base can be specifically recognized by different drugs at position −1 (Capranico et al., 1997). Our model might also be effective for topoisomerase I poisons, as suggested by very recent work on the crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA (Redimbo et al., 1998). In fact, based on chemical, structural, and biochemical evidence, the binding mode proposed for the anticancer drug camptothecin (exhibiting G+1 specificity) at the topoisomerase I-DNA complex suggests an effective stacking interaction of the guanine residue with the planar ring system of the drug. This is confirmed by the fact that TS corresponds to DS for indolocarbazole derivatives having +1 specificity (Baillly et al., 1997, 1998).

From the aforementioned results, some useful insight can be gained into the molecular basis of the TS. It appears that, for +1-specific agents, the drug-DNA contacts are primarily responsible for base selectivity; the interaction between the protein and the poison does not play a major role in stabilizing a specific ternary complex intermediate. As a result, it should be possible to predict the likely location of +1 cleavage stimulation along the DNA chain from binary complex studies. As a corollary to the model presented here, a +1 cleavage-stimulating agent should be characterized by high affinity for single-stranded DNA. These findings have useful implications for the design of novel topoisomerase poisons. Studies on the DNA-binding properties of other topoisomerase II poisons exhibiting +1 specificity, such as saintopin (Leteurte et al., 1994) and NSC665517 [2-methyl-3-[2-(6-oxopropylidymethylamino)phenyl]-6,8-dibromo-4-(3H)-quinazolinone] (Gupta et al., 1995) (both guanine specific), are warranted to confirm the general applicability of our model and further elucidate the mode of base selection in drug-stimulated DNA cleavage.

References


Leteurte F, Madalengoitia J, Orr A, Guzi TJ, Lehnter E, Macdonald T, and Pom-


Send reprint requests to: Dr. Manlio Palumbo, Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy. E-mail: mpalumbo@purple.dsfarm.unipd.it